FDA Grants Novartis Breakthrough Therapy Designation for CAR-T Cell Treatment – Bioscience Technology
Bioscience Technology |
FDA Grants Novartis Breakthrough Therapy Designation for CAR–T Cell Treatment
Bioscience Technology The investigational chimeric antigen receptor T cell (CAR-T) therapy, known as CTL019 was first developed by researchers at the University of Pennsylvania. Novartis and Penn entered into a global collaboration for development and commercialization of … |
